Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($2.57), $1.97 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $321.1 million versus the consensus estimate of $310.82 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.